GEN-MKT-18-7897-A
Aug 22, 2017 | Blogs, Technology | 0 comments
Scientists and analysts across all fields of testing and research are increasingly challenged by complex samples requiring advanced analytical selectivity. And where LC-MS/MS sensitivity alone is not enough to meet the demands of modern day quantitative performance, Differential Ion Mobility Spectrometry (DMS) has proven to be a valuable addition.
Break Through the Selectivity Barrier of Your LC/MS-MS SeparationsSCIEX offers the most innovative solution with its SelexION® DMS Technology. It is a small, planar mobility cell that is easy to install (in less than 2 minutes), easy-to-use and can significantly increase analytical separation power. No other ion mobility separation tool offers the reproducibility, robustness, and simplicity to deliver highly selective and sensitive quantitative and qualitative analyses, within a UHPLC time scale.
How does SelexION make this possible?The SelexION DMS technology separates ions based on differences in mobility in two different regions of the field dependent mobility curve. Due to its small size, the system can operate with very short ion residence times with optimal performance when using chemical modifiers. The DMS device can also be used in ‘transparent mode’ to allow for maximal workflow flexibility.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network